市場調查報告書

免疫療法藥的全球市場:成長率,趨勢及預測分析(2019年∼2024年)

Immunotherapy Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 649742
出版日期 內容資訊 英文 116 Pages
商品交期: 2-3個工作天內
價格
免疫療法藥的全球市場:成長率,趨勢及預測分析(2019年∼2024年) Immunotherapy Drugs Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年09月01日內容資訊: 英文 116 Pages
簡介

全球免疫療法藥市場在2019年∼2024年的預測期間內,預計將以13%的年複合成長率成長。推動免疫療法藥市場成長的主要原因,為標靶治療比傳統治療方法的採用增多,生物相似藥的出現,慢性疾病和文明病的盛行率上升,單株抗體的需求高漲等。

本報告提供全球免疫療法藥市場相關調查分析,市場概要,市場動態,市場區隔,各地區的市場分析,競爭情形,主要企業等相關的系統性資訊。

目錄

第1章 簡介

  • 調查的成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 標靶治療比傳統的療法的採用增多
    • 生物相似藥的出現
    • 慢性疾病和文明病的盛行率上升
    • 單株抗體的需求高漲
  • 市場阻礙因素
    • 免疫療法治療的高成本
    • 在產品開發週期的高損耗率
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 競爭力的強度

第5章 市場區隔

  • 藥物的各類型
    • 單株抗體
    • 疫苗
    • 免疫查核點抑制劑
    • α干擾素及β
    • 白細胞介素
    • 其他
  • 各治療領域
    • 癌症
    • 自體免疫疾病及發炎性疾病
    • 感染疾病
    • 其他
  • 各終端用戶
    • 醫院/診療所
    • 癌症研究中心
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲地區
    • 南美

第6章 競爭情形

  • 企業概要
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca
    • Bristol-Myers Squibb
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline PLC
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novartis AG
    • UbiVac

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 60463

Market Overview

The Immunotherapy Drugs Market studied is anticipated to grow with a CAGR of 13%, during the forecast period (2019-2024). The major factors attributing to the growth of the Immunotherapy drugs market are such as the rising adoption of targeted therapy over traditional therapy, emergence of biosimilars, rising prevalence of chronic diseases and lifestyle disorders and also raising demand for monoclonal antibodies.

For instance, over the last decade, there has been a continuous rise in the prevalence of several chronic diseases, which, in several cases, need immune-based therapies. Some of the major chronic diseases include cancer, kidney failure, and heart diseases, among others. Several lifestyle disorders, both chronic and non-communicable diseases, such as hypertension, diabetes, obesity, and depression, among others, need critical care during hospitalization. Chronic diseases in critically ill patients are often characterized by long hospital stays, intense suffering, and prolonged dependence, with substantial consumption of resources. Mostly, the conditions become very complex, exhibiting combined disorders related to neurological, endocrine, metabolic, immunologic, and muscle disorders, where biological therapy plays an essential role. Thus, the rise in the number of diseases and associated disorders are among the major primary reasons for the growth of this immunotherapy drugs market.

Scope of the Report

Immunotherapy relates to a type of biologic therapy for cancer treatment, to boost the body's natural defenses to fight cancer. It may work in stopping or slowing the growth of cancer cells, stopping cancer from spreading in other parts of the body, and in the improvement of the immune system. These therapies are made by the body or in a laboratory, to improve or restore the immune system function.

Key Market Trends

Cancer is Expected to Hold the Major Share in the Therapy Area Segment of Immunotherapy Market

As per a 2014 publication in the Cancer Research journal, by 2030, an estimated 2.1 million people in the United States are expected to be diagnosed with cancer, each year and similarly, the prevalence of cancer is more or less same across the globe too. And this cancer prevalence is expected to be same in the coming years, which is helping the market growth. As per the present clinicalTrials.gov status, nearly 1,400 clinical trials are being listed, out of which, more than 800 are being conducted in the United States, nearly 400 in European countries, and other prominent countries, such as China, Australia, and Canada. The growth of immunotherapies in developed markets is high, due to increased R&D, with better government policies for supporting clinical trials through findings and campaigns, in order to raise awareness regarding several kinds of cancer.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. This is due to the increasing incidence of cancers, rising geriatric population, growing preference, and adoption rate of immunotherapy rates across the region. In the North America region, the United States holds the largest market share. And the factors, such as increased awareness among people for the early detection of diseases, better reimbursement policies, healthcare expenditure with better infrastructure and rising prevalence of chronic and lifestyle disorders are primary factors raising the immunotherapy market in this country.

Competitive Landscape

The immunotherapy drugs market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising patient awareness levels and high prevalence of diseases such as cancer, few other smaller players are also expected to enter into the market in the coming years. Some of the major players of the market are AbbVie Inc., Amgen Inc., AstraZeneca, GlaxoSmithKline PLC, and F. Hoffmann-La Roche AG are among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Adoption of Targeted Therapy over Traditional Therapy
    • 4.2.2 Emergence of Biosimilars
    • 4.2.3 Rising Prevalence of Chronic Diseases and Lifestyle Disorders
    • 4.2.4 Rising Demand for Monoclonal Antibodies
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Immunotherapy Treatment
    • 4.3.2 High Attrition Rate in the Product Development Cycle
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of Drug
    • 5.1.1 Monoclonal Antibodies
    • 5.1.2 Vaccines
      • 5.1.2.1 Preventive Vaccines
      • 5.1.2.2 Therapeutic Vaccines
    • 5.1.3 Checkpoint Inhibitors
    • 5.1.4 Interferons Alpha and Beta
    • 5.1.5 Interleukins
    • 5.1.6 Other Type of Drugs
  • 5.2 By Therapy Area
    • 5.2.1 Cancer
    • 5.2.2 Autoimmune and Inflammatory Diseases
    • 5.2.3 Infectious Diseases
    • 5.2.4 Other Therapy Areas
  • 5.3 By End User
    • 5.3.1 Hospitals/Clinics
    • 5.3.2 Cancer Research Centers
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Amgen Inc.
    • 6.1.3 AstraZeneca
    • 6.1.4 Bristol-Myers Squibb
    • 6.1.5 F. Hoffmann-La Roche AG
    • 6.1.6 GlaxoSmithKline PLC
    • 6.1.7 Johnson & Johnson
    • 6.1.8 Merck & Co. Inc.
    • 6.1.9 Novartis AG
    • 6.1.10 UbiVac

7 MARKET OPPORTUNITIES AND FUTURE TRENDS